Unlocking TNFi Treatment Success: Does HLA-B27 Hold the Key in Axial Spondyloarthritis?
"New research explores how HLA-B27 status impacts treatment outcomes in Ankylosing Spondylitis and non-radiographic axial spondyloarthritis, offering insights for personalized medicine."
Axial spondyloarthritis (axSpA) is a type of inflammatory arthritis that primarily affects the spine and sacroiliac joints, leading to chronic pain, stiffness, and reduced mobility. AxSpA encompasses both Ankylosing Spondylitis (AS), where structural damage to the joints is visible on X-rays, and non-radiographic axSpA (nr-axSpA), where such damage isn't yet apparent.
Tumor necrosis factor inhibitors (TNFi) have revolutionized the treatment of axSpA, offering significant relief from symptoms and improving quality of life for many patients. However, not everyone responds equally well to TNFi therapy, and predicting treatment outcomes remains a challenge.
The HLA-B27 gene is strongly associated with axSpA, but its precise role in disease development and treatment response is still being investigated. This article delves into a recent study that explored how HLA-B27 status influences the effectiveness of TNFi treatment in patients with AS and nr-axSpA, potentially paving the way for more personalized treatment approaches.
Diagnosis Uses Multiple Clues
No single test diagnoses ankylosing spondylitis, and an HLA-B27 blood test is one source of information rather than a diagnosis on its own. The NIAMS source notes that a person can carry HLA-B27 and never develop the disease. A 2024 overview also describes MRI as a tool for detecting early inflammatory changes and says HLA-B27 can help confirm a diagnosis. One 2025 source reports that, for chronic low back pain lasting more than three months and starting before age 45, inflammatory-back-pain criteria and HLA-B27 testing have post-test probabilities of 14% and 32%, respectively.
From Early Descriptions to Axial SpA
Ankylosing spondylitis has a history extending to antiquity, but Bernard Connor published its first anatomical description in 1695, based on the skeleton of a patient with advanced disease. The term axial spondyloarthritis (axSpA) was later adopted to include both ankylosing spondylitis and non-radiographic axSpA. The historical account also notes that diagnostic criteria incorporated genetic features, including family history of related conditions or HLA-B27, alongside response to NSAIDs. A 2023 review reports that, beyond HLA-B*27 alleles, 12 loci had been identified in populations of European ancestry, with two additional associated loci also noted in its snippet.
HLA-B27: A Predictor of TNFi Treatment Success?
A nationwide cohort study from Denmark, utilizing data from the DANBIO registry, examined the association between HLA-B27 status and TNFi treatment outcomes in 1,250 patients with axSpA. The study included individuals with both AS and nr-axSpA who were starting TNFi therapy for the first time.
- Baseline Differences: The study revealed that patients with nr-axSpA tended to have higher subjective disease activity at the start of TNFi treatment compared to those with AS.
- Treatment Response: Despite these baseline differences, the overall response rates to TNFi therapy were similar between the two groups after adjusting for confounders.
- HLA-B27 Impact: Importantly, the study found that HLA-B27 positivity was associated with better treatment adherence and higher response rates, irrespective of whether patients had AS or nr-axSpA.
Recent Review Coverage
The supplied Nature Reviews Rheumatology page lists articles about ankylosing spondylitis. A 2026 Frontiers in Pharmacology article is titled “Biologic and targeted synthetic therapies in ankylosing…” and its supplied snippet identifies radiological features of ankylosing spondylitis. These listings establish that review coverage includes the disease and targeted therapies, but the supplied material does not provide findings or treatment-response estimates from either source.
Limits of the Available Evidence
The supplied study description compares baseline disease activity and treatment effectiveness in biologic-naive patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis who start TNF inhibitors, and says it examines HLA-B27 status and potential confounders. The snippet does not report the comparison's results, so it cannot establish from the material provided whether HLA-B27 predicts better or worse TNFi effectiveness. The other listed source discusses possible gene therapy and precision-medicine approaches for HLA-B27-associated diseases, but its snippet describes possibilities rather than demonstrated treatment outcomes.
Phenotypes and HLA-B27
A 2025 conference abstract states that patients with ankylosing spondylitis exhibit different phenotypes according to HLA-B27 status. The supplied abstract snippet does not specify which phenotypes differ or provide comparative treatment-response results. The IntechOpen chapter identifies HLA-B27's roles in ankylosing spondylitis pathogenesis and clinical manifestations as frequently discussed topics over the preceding three decades. Together, these sources establish the comparison as an active topic but do not supply enough detail to quantify the differences.
Personalized Treatment Strategies: Tailoring TNFi Therapy to HLA-B27 Status
The study's findings highlight the potential for personalized treatment strategies in axSpA based on HLA-B27 status. While TNFi therapy remains a cornerstone of treatment, understanding a patient's HLA-B27 status may help clinicians better predict treatment response and optimize management plans.
A Strong Association, Not a Cure
A 2025 article describes axial spondyloarthritis, including classical ankylosing spondylitis, as having the strongest association with HLA-B27 within the spondyloarthritis spectrum. It says this association is why axSpA is often considered among the “MHC-I-pathies.” The supplied snippet frames HLA-B27 as a potential target for a cure, but does not establish that targeting it has produced a cure.
Research Directions Ahead
A review titled “Breaking boundaries in ankylosing spondylitis: how innovative cell therapies reshape immunity, drive cutting-edge advances, and face future challenges” identifies cell therapies as an area of research and highlights unresolved challenges. A Spondylitis Association article marks 50 years since HLA-B27's relation to ankylosing spondylitis was discovered and reflects on its past, present, and future impact in rheumatology. Another listed source describes 2025 research interests including new gene variants, improved diagnostics, personalized therapies, genetics, and the microbiome. The supplied snippets present these as research directions, not established clinical advances.
HLA-B27 and Clinical Outcomes
A 2020 conference abstract reports that approximately 80%–90% of white patients with ankylosing spondylitis express HLA-B27, compared with fewer than 8% of the general population. It also states that HLA-B27-negative status predicts a worse response to TNF inhibitors in patients with ankylosing spondylitis. The abstract mentions research on HLA-B27 status and secukinumab efficacy, but the supplied snippet does not give its results. A separate review describes ankylosing spondylitis as a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, with pain and stiffness.
For HLA-B27 positive patients, these results offer reassurance that TNFi therapy is likely to be effective, potentially leading to better adherence and long-term outcomes. For HLA-B27 negative patients, clinicians may need to consider alternative treatment strategies or more closely monitor treatment response to ensure optimal disease control.
Further research is needed to fully elucidate the mechanisms by which HLA-B27 influences TNFi treatment response in axSpA. However, this study provides valuable insights that could ultimately lead to more effective and personalized treatment approaches for individuals living with this chronic inflammatory condition.